NCT00763035

Comparison of Dobutamine and Regadenoson Stress Cardiac Magnetic Resonance (MR)

Comparison of Dobutamine and Regadenoson Stress CMR

• Status: Terminated
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 14 (actual)
• Sponsor: Wake Forest University Health Sciences · Academic / Other
• Sex: All
• Age: 40 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

The goal of this research is to determine the utility of Regadenoson (Lexiscan)for use as an imaging agent with cardiac MR. If found useful, it will help us establish a protocol for regadenoson stress MR perfusion (Regadenoson stress test with cardiac MR).The investigators will compare regadenoson with dobutamine so each participant will undergo two studies. A cardiac MR stress test with regadenoson and with dobutamine. The investigators participants will include patients with history of COPD and Asthma, so it will also help us determine feasibility of Regadenoson in these patient's subgroups.

Conditions

• Coronary Artery Disease
• Asthma
• Chronic Obstructive Pulmonary Disease (COPD)
• Angina

Interventions

Type	Name	Description
DRUG	Regadenoson	Each participant will receive regadenoson 0.4mg (5ml) one time bolus dose at one visit.
DRUG	Dobutamine	Each participant will receive dobutamine infusion (as per protocol to achieve a target heart rate of 85% of predicted for age) at another visit.

Timeline

• Start date: 2009-01-01
• Primary completion: 2010-12-01
• Completion: 2011-03-01
• First posted: 2008-09-30
• Last updated: 2018-09-26
• Results posted: 2018-09-26

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study